Methods for treatment of breast cancer nonresponsive to trastuzumab

Abstract

The present invention provides a method of treating breast cancer that is nonresponsive to treatment with trastuzumab, comprising administering to a subject in need of such treatment a therapeutically effective amount of compound N-(3,4-dichloro-2-fluorophenyl)-7-({[(3aR,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, or a pharmaceutically acceptable salt thereof.

What is claimed is: 
     
         1 . A method of treating breast cancer that is nonresponsive to treatment with trastuzumab, comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of Formula 1 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         2 . A compound of Formula 1 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, for use in treating breast cancer that is nonresponsive to treatment with trastuzumab. 
     
     
         3 . Use of a compound of Formula 1 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating breast cancer that is nonresponsive to treatment with trastuzumab. 
     
     
         4 . The method of  claim 1 , wherein the compound, or a pharmaceutically acceptable salt thereof, is a stereoisomer selected from the group consisting of N-(3,4-dichloro-2-fluorophenyl)-7-({[(3aR,5r,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine and N-(3,4-dichloro-2-fluorophenyl)-7-({[(3aR,5s,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, or a pharmaceutically acceptable salt of the stereoisomer. 
     
     
         5 . The method as in  claim 1  or  4 , wherein the pharmaceutically acceptable salt is the salt of p-toluenesulfonic acid. 
     
     
         6 . The method as in  claim 1 ,  4  or  5 , wherein the subject is human and the breast cancer has not been treated with trastuzumab. 
     
     
         7 . The method as in  claim 1 ,  4  or  5 , wherein the subject is human and the breast cancer has been treated with trastuzumab. 
     
     
         8 . The method as in  claim 1 ,  4  or  5 , comprising co-administering the compound of Formula 1 and trastuzumab. 
     
     
         9 . The method as in  claim 1 ,  4  or  5 , wherein the subject is human and the breast cancer is PTEN-negative. 
     
     
         10 . The method as in  claim 1 ,  4  or  5 , wherein the subject is human and the breast cancer is positive for mutations in the PIK3CA gene. 
     
     
         11 . The method as in  claim 1 ,  4  or  5 , wherein the subject is human and the breast cancer expresses a truncated ErbB2 receptor that lacks the extracellular domain to which trastuzumab binds. 
     
     
         12 . The method as in  claim 1 ,  4  or  5 , wherein the subject is human and the breast cancer overexpresses one or more RTKs selected from the group consisting of EGFR family members, IGF-1R and HGFR.